Acute and chronic effects of thyrotropin-releasing hormone (TRH) on stabilogram in spinocerebellar degenerations.

Abstract

A single blind cross over trial was conducted of thyrotropin-releasing hormone treatment in 7 patients with spinocerebellar degenerations. Patients received daily 2 mg of thyrotropin releasing hormone intramuscularly during the 2 week treatment period. Acute beneficial effect on stabilogram was demonstrated, but significant therapeutic efficacy in the chronic treatment failed to be demonstrated, though a trend of effectiveness was observed.

• Authors: M Yoshida, T Nakanishi, Y Komatsu
• Journal: The Tohoku journal of experimental medicine (Tohoku J Exp Med) Vol. 148 Issue 3 Pg. 327-31 (Mar 1986) ISSN: 0040-8727 [Print] Japan
• PMID: 3085285 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Thyrotropin-Releasing Hormone

Topics

• Adult
• Cerebellar Ataxia (drug therapy, physiopathology)
• Cerebellar Diseases (drug therapy, physiopathology)
• Clinical Trials as Topic
• Eye Movements (drug effects)
• Female
• Humans
• Male
• Middle Aged
• Spinal Cord Diseases (drug therapy, physiopathology)
• Thyrotropin-Releasing Hormone (therapeutic use)
• Time Factors